Viewpoint discusses implications of CMS model for expanding access to obesity medications and interventions for beneficiaries.
This Viewpoint discusses a new Centers for Medicare & Medicaid Services (CMS) model to expand access to novel obesity medications and lifestyle interventions for Medicare and Medicaid beneficiaries.
No takes yet. Share an insight, caveat, or question.
Gasoyan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: